Sign Up
Stories
Aquadex SmartFlow® System's Potential
Share
89bio to Present pegozafermin for NASH a...
Evolut TAVR Triumphs in SMART Trial
ANJESO Drug Insight and Market Forecast
Innovative Dialysis Technology Showcased
Rare Gastrointestinal Diseases Market Ex...
Overview
API
Nuwellis, Inc. showcases the potential of Aquadex SmartFlow® system's aquapheresis therapy for patients with fluid overload due to end-stage liver disease. The case series at Mount Sinai Hospital highlights the effectiveness of Aquadex in addressing clinical gaps for patients with alcohol-associated cirrhosis.
Ask a question
How could the success of Aquadex SmartFlow® system influence the research and development of other therapies for liver diseases?
How might the commercialization of Aquadex SmartFlow® system impact the healthcare industry's approach to managing fluid overload in patients with liver disease?
What are the potential implications of Aquadex SmartFlow® system's potential for patients with liver disease on the development of new treatment options?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage